logo
Sign in

Crinetics Pharmaceuticals, Inc.

SAN DIEGO, CA · Biotech · Acquired

Small molecule biased somatostatin sst2A agonists for hormone-secreting tumors

Claim this profile

Follows are private to you and power your alerts

Updated · crinetics.com

Sector
Biotech
Headquarters
SAN DIEGO, CA
Latest Form D
$350M, Mar 2024
Total capital
$436M
Federal grants
$8.5M
9 awards · 2015–2019
Rank in peer group#68 of 514
Private capital raised
$428M
3 Form D · last Mar 2024
32 months since last filing
Federal contracts
None on recordNo federal contract awards found.
Granted patents
17
23 pending · first 2022
Rank in peer group#7 of 514

Capital timeline

20152017201920212023FEDERAL ↑EQUITY ↓Cumulative $436M$784K$716K$2.8M$1.4M$999K$897K1st Form D$18M2nd Form D$60M3rd Form D$350M
20152017201920212023FEDERAL ↑EQUITY ↓Cumulative $436M$2.8M$1.4M$897K2nd Form D$60M3rd Form D$350M

Latest events

  • Private capital raisedForm D · SEC · 3rd filing$350M
  • Federal grantHealth and Human S · Phase II · Nonpeptide, oral somatostatin agonists for congenital hyperinsulinemias$897K
  • Federal grantHealth and Human S · Phase II · Nonpeptide, oral somatostatin agonists for congenital hyperinsulinemias$999K
  • Federal grantHealth and Human S · Phase II · Biased Agonism In GPCR Drug Discovery: Application To Somatostatin Agonists$1.4M
  • Private capital raisedForm D · SEC · 2nd filing$60M
  • Federal grantHealth and Human S · Phase I · Discovery of novel small molecule drugs for Cushing's disease$300K
  • Federal grantHealth and Human S · Phase I · Nonpeptide oral somatostatin agonists for congenital hyperinsulinemias$297K
  • Private capital raisedForm D · SEC · 1st filing$18M
Show 4 earlier federal awards
  • Federal grantHealth and Human S · Phase II · Biased Agonism In GPCR Drug Discovery: Application To Somatostatin Agonists$2.8M
  • Federal grantHealth and Human S · Phase II · Nonpeptide Kisspeptin Antagonists for PCOS and HPG axis control$716K
  • Federal grantHealth and Human S · Phase II · Small molecule somatostatin agonists for neuropathic pain$326K
  • Federal grantHealth and Human S · Phase II · Nonpeptide Kisspeptin Antagonists for PCOS and HPG axis control$784K

Node area is scaled to amount. Form D reports securities sold, which can differ from an announced round; filings are numbered in the order they were made.

Federal first

10months

from Crinetics Pharmaceuticals, Inc.’s first federal award to its first private round.

First federal award · Jan 2015
Health and Human S · $784K
First Form D · Nov 2015
$18M · 1st Form D
Awards before first raise
2 awards

An association in public records, not a cause or a prediction.

Standing among 514 peers

Line = median

Biotech · Molecule

  • Federal grants#68 · top 13%
  • Granted patents#7 · top 1%

Cumulative measures favor older companies. Rankings describe position today, not outcome. Below the median, ranks show as a band rather than a number.

Founders and team

Researcher links verified by same-company patents and grants
  • Richard Scott StruthersResearcherExecutive Officer, DirectorLinked by $2.8M in grants as PI
  • STEPHEN VIVALDI BETZResearcherExecutive OfficerLinked by $3.7M in grants as PI
  • CAMILLE SCOTT BEDROSIAN, M.D.DirectorNamed in SEC Form D filings
  • CAREN SCOTT DEARDORFDirectorNamed in SEC Form D filings
  • DANA VIVALDI PIZZUTIExecutive OfficerNamed in SEC Form D filings
  • Jack B. NielsenDirectorNamed in SEC Form D filings
Show all 25 people
  • JAMES VIVALDI HASSARDExecutive OfficerNamed in SEC Form D filings
  • JEFF VIVALDI KNIGHTExecutive OfficerNamed in SEC Form D filings
  • Mahendra Scott ShahDirectorNamed in SEC Form D filings
  • Marc Scott WilsonExecutive OfficerNamed in SEC Form D filings
  • Mason Scott FreemanDirectorNamed in SEC Form D filings
  • Mason Scott Freeman, M.D.DirectorNamed in SEC Form D filings
  • Matthew K. FustDirectorNamed in SEC Form D filings
  • RICHARD SCOTT STRUTHERS, PhDExecutive Officer, DirectorNamed in SEC Form D filings
  • Richard Scott Struthers, Ph.DExecutive Officer, DirectorNamed in SEC Form D filings
  • ROGERIO VIVALDI COELHO, M.D.DirectorNamed in SEC Form D filings
  • STEPHANIE SCOTT OKEYDirectorNamed in SEC Form D filings
  • Steve Scott KaldorDirectorNamed in SEC Form D filings
  • Steve Scott Kaldor, Ph.DDirectorNamed in SEC Form D filings
  • Wendell Scott WierengaDirectorNamed in SEC Form D filings
  • WENDELL SCOTT WIERENGA, PhDDirectorNamed in SEC Form D filings
  • Wendell Scott Wierenga, Ph.DDirectorNamed in SEC Form D filings
  • WESTON SCOTT NICHOLS, PhDDirectorNamed in SEC Form D filings
  • Weston K. Nichols, Ph.DDirectorNamed in SEC Form D filings
  • YunFei F. ZhuExecutive OfficerNamed in SEC Form D filings

What it has protected

USPTO · 17 granted of 40
  • PendingSpirocyclic Piperidine Melanocortin SUBTYPE-2 Receptor (MC2R) Antagonists And Uses ThereofUSPTOApplication 19357323
  • PendingMelanocortin SUBTYPE-2 Receptor (MC2R) Antagonists And Uses ThereofUSPTOApplication 19372677
  • PendingCrystalline Forms Of Somatostatin ModulatorsUSPTOApplication 19639569
Show all 40 patent records

Related companies, and why

  • Granite BioSimilar federal contract value in Biotech · null in contracts
  • Emalex BiosciencesSimilar federal contract value in Biotech · null in contracts
  • ChemomabSimilar federal contract value in Biotech · null in contracts
  • Arch Innotek, LLCSimilar federal contract value in Biotech · null in contracts
  • MYOFINITY BIOSCIENCES INCSimilar federal contract value in Biotech · null in contracts
  • FORGE THERAPEUTICS INCSimilar federal contract value in Biotech · null in contracts

Regulatory activity · Biotech

Sector-level, not company-level

Rules are matched to sector, not to company. Recent activity in a sector is context rather than a signal about this business — until rules are matched to what a company actually builds, the section is shown as context and nothing more.

Sources

Federal grants from SBIR/STTR, NIH, NSF and DoD records. Federal contracts from USAspending.gov. Private capital from SEC Form D. Patents from USPTO. Publications from OpenAlex. Regulatory activity from the Federal Register. Press matched on company name.

How to read this page

Figures show associations in public records, not causes or predictions. Nothing here is investment advice. An em-dash means no record was found under this company's name, not that none exists.

Data freshness

SEC Form D filings through . SBIR and STTR awards through .